Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.
Torsten O. Nielsen, MD, PhD, FRCPC
Advertisement
Articles by Torsten O. Nielsen, MD, PhD, FRCPC
Torsten O. Nielsen discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.
Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.
Advertisement
Latest Updated Articles
The Clinical Utility of Ki67 in Breast CancerPublished: July 19th 2013 | Updated:
The Difference Between the PAM50 Assay and Other Molecular TestsPublished: September 6th 2013 | Updated:
The Challenges of Using Ki67 as a Tool in Breast CancerPublished: November 1st 2013 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
